23andMe CEO Wojcicki on Telehealth, Covid Research

The transcript discusses 23andMe's integration of telehealth and genetic data into primary care, emphasizing the potential of telehealth to drive future business. It highlights ongoing COVID-19 research, particularly on long COVID, and the importance of genetic insights. The role of genetics in drug discovery is explored, with a focus on 23andMe's partnership with GSK. The transition to a public company and the vision of making genetics a core part of healthcare are also covered.

What is the significance of having a human genetic foundation in drug discovery according to 23andMe?

How does 23andMe's approach differ from traditional telemedicine and diagnostics?

What is the long-term vision of 23andMe regarding genetics in healthcare?